Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence” cover art

Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”

Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”

Listen for free

View show details
In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
adbl_web_anon_alc_button_suppression_t1
No reviews yet